Effect of Post-Discharge Oral Nutritional Supplements on Nutritional Status in Patients after Gastrectomy: A Systematic Review and Meta-Analysis.

J Vis ExpSep 1, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)

Wenqing Xu, Chuyuan Niu

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of post-discharge oral nutritional supplements (ONS) on nutritional status in 1,736 patients after gastrectomy for gastric cancer. ONS significantly reduced absolute body-weight loss (WMD: 0.75 kg) and percentage body-weight loss (WMD: 1.42) compared to control care, although no significant differences were observed in body composition or handgrip strength.

Key findings

  • ONS reduced absolute body-weight loss by 0.75 kg compared to control care.
  • ONS decreased percentage body-weight loss by 1.42 compared to control care.
  • No significant differences in body composition or handgrip strength were found.
  • Adverse-event incidence was similar between ONS and control groups (RR: 1.17).

Why it matters

Postoperative nutritional support is crucial for recovery after gastrectomy. This review highlights the potential of ONS to mitigate weight loss, which can influence recovery and overall patient outcomes.

What to keep in mind

The review is limited by the small number of trials and substantial heterogeneity in primary weight outcomes.

Source

PubMed · PMID 42683908

Published in J Vis Exp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.